Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Amortization - Intangibles (2016 - 2026)

Integra Lifesciences Holdings' Amortization - Intangibles history spans 17 years, with the latest figure at $3.8 million for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles rose 1.43% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.0 million, a 29.76% decrease, with the full-year FY2025 number at $15.0 million, down 29.76% from a year prior.
  • Amortization - Intangibles hit $3.8 million in Q4 2025 for Integra Lifesciences Holdings, up from $3.7 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for IART hit a ceiling of $10.1 million in Q1 2024 and a floor of $3.0 million in Q2 2023.
  • Historically, Amortization - Intangibles has averaged $4.0 million across 5 years, with a median of $3.7 million in 2024.
  • Biggest five-year swings in Amortization - Intangibles: soared 225.19% in 2024 and later plummeted 63.35% in 2025.
  • Tracing IART's Amortization - Intangibles over 5 years: stood at $4.1 million in 2021, then decreased by 13.08% to $3.5 million in 2022, then dropped by 14.37% to $3.0 million in 2023, then grew by 22.45% to $3.7 million in 2024, then grew by 1.43% to $3.8 million in 2025.
  • Business Quant data shows Amortization - Intangibles for IART at $3.8 million in Q4 2025, $3.7 million in Q3 2025, and $3.8 million in Q2 2025.